Filing Details
- Accession Number:
- 0001209191-10-020352
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-04-02 13:00:00
- Reporting Period:
- 2010-03-31
- Filing Date:
- 2010-04-02
- Accepted Time:
- 2010-04-02 18:47:54
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197018 | Anthony N Coles | C/O Onyx Pharmaceuticals, Inc. 2100 Powell St. Emeryville CA 94608 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2010-03-31 | 21,000 | $0.00 | 93,064 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2010-04-01 | 8,914 | $30.10 | 84,150 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-04-01 | 8 | $30.30 | 84,142 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2010-03-31 | 147,000 | $0.00 | 147,000 | $30.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 147,000 | 2020-03-31 | No | 4 | A | Direct |
Footnotes
- Includes an aggregate of 1,261 shares purchased through the issuer's ESPP.
- Shares sold pursuant to a 10b5-1 plan.
- 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
Billionaire Hedge Funds
